Supernus Pharmaceuticals (SUPN) Earns “Buy” Rating from Mizuho

Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “buy” rating reissued by research analysts at Mizuho in a research note issued on Friday, TipRanks reports.

SUPN has been the subject of a number of other research reports. BidaskClub raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, April 4th. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Friday, May 10th. Cantor Fitzgerald set a $60.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 8th. B. Riley set a $65.00 target price on shares of Supernus Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, March 4th. Finally, ValuEngine downgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $56.13.

Shares of NASDAQ SUPN traded down $0.34 on Friday, reaching $33.25. 336,765 shares of the company traded hands, compared to its average volume of 591,344. Supernus Pharmaceuticals has a fifty-two week low of $30.05 and a fifty-two week high of $61.25. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.77 and a quick ratio of 2.59. The company has a market cap of $1.74 billion, a P/E ratio of 16.22, a P/E/G ratio of 1.13 and a beta of 1.57.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Tuesday, May 7th. The specialty pharmaceutical company reported $0.34 EPS for the quarter, missing the Zacks’ consensus estimate of $0.44 by ($0.10). Supernus Pharmaceuticals had a net margin of 25.49% and a return on equity of 23.60%. The company had revenue of $85.50 million for the quarter, compared to analyst estimates of $102.26 million. During the same period in the prior year, the company earned $0.49 EPS. The company’s revenue was down 5.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Supernus Pharmaceuticals will post 2.24 EPS for the current year.

In related news, CFO Gregory S. Patrick sold 20,000 shares of the stock in a transaction that occurred on Wednesday, February 27th. The shares were sold at an average price of $41.53, for a total transaction of $830,600.00. Following the completion of the sale, the chief financial officer now owns 67,896 shares of the company’s stock, valued at approximately $2,819,720.88. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 6.20% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. Meeder Asset Management Inc. boosted its holdings in Supernus Pharmaceuticals by 511.1% in the 4th quarter. Meeder Asset Management Inc. now owns 880 shares of the specialty pharmaceutical company’s stock worth $30,000 after acquiring an additional 736 shares during the period. Rockefeller Capital Management L.P. boosted its holdings in Supernus Pharmaceuticals by 232.9% in the 1st quarter. Rockefeller Capital Management L.P. now owns 1,082 shares of the specialty pharmaceutical company’s stock worth $38,000 after acquiring an additional 757 shares during the period. Financial Gravity Wealth Inc. purchased a new position in Supernus Pharmaceuticals in the 1st quarter worth approximately $44,000. Advisor Group Inc. boosted its holdings in Supernus Pharmaceuticals by 17.2% in the 4th quarter. Advisor Group Inc. now owns 2,082 shares of the specialty pharmaceutical company’s stock worth $69,000 after acquiring an additional 306 shares during the period. Finally, Cutler Group LP purchased a new position in Supernus Pharmaceuticals in the 4th quarter worth approximately $89,000. Hedge funds and other institutional investors own 98.62% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

Recommended Story: Investing strategies using the yield curve

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.